DCPH - Deciphera Pharmaceuticals GAAP EPS of -$0.57 beats by $0.05 revenue of $38.3M beats by $1.98M

2023-08-09 07:28:49 ET

• Deciphera Pharmaceuticals press release ( NASDAQ: DCPH ): Q2 GAAP EPS of -$0.57 beats by $0.05 .
• Revenue of $38.3M (+17.8% Y/Y) beats by $1.98M .
• As of June 30, 2023, cash, cash equivalents, and marketable securities were $389.4 million, compared to $426.3 million as of March 31, 2023.
• Based on its current operating plans, Deciphera expects its current cash, cash equivalents, and marketable securities together with anticipated product, royalty, and supply revenues, but excluding any potential future milestone payments under its collaboration or license agreements, will enable the Company to fund its operating and capital expenditures into 2026.

For further details see: